---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064439"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:56:55.114063+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q1 2025 revenue $40.8M (-10% YoY); net loss $26.0M, adj EBITDA loss $16.9M

## Summary
- First-quarter revenue $40.8M, down 10% YoY; consumables -16%, instruments +24%, services -16%.
- Net loss $26.0M improved 19% YoY ($32.2M); adjusted EBITDA loss $16.9M improved 29%.
- Non-GAAP gross margin 53.2%, down from 56.2% in Q1 2024 due to volume, mix, and pricing.
- Cash & equivalents $260.7M, no material debt; FY2025 revenue outlook reaffirmed at $165-175M.
- Operating expenses fell 38% YoY to $52.7M, driven by merger cost synergies and SBS productivity gains.

## SEC filing metadata
- accession: 0000950170-25-064439
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/0000950170-25-064439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/lab-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064439
- JSON: https://secwatch.observer/filing/0000950170-25-064439.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.